

Maureen Rischmueller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11120846/publications.pdf>

Version: 2024-02-01

56
papers

3,214
citations

172457

29
h-index

168389

53
g-index

57
all docs

57
docs citations

57
times ranked

4335
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. <i>Nature Genetics</i> , 2013, 45, 1284-1292. | 21.4 | 427 |
| 2 | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet</i> , The, 2017, 390, 457-468. | 13.7 | 360 |
| 3 | Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 1647-1654. | 6.7 | 235 |
| 4 | Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. <i>European Journal of Immunology</i> , 1997, 27, 1726-1736. | 2.9 | 161 |
| 5 | Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2020, 383, 1511-1521. | 27.0 | 151 |
| 6 | Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050. | 0.9 | 132 |
| 7 | Determinant spreading: lessons from animal models and human disease. <i>Immunological Reviews</i> , 1998, 164, 209-229. | 6.0 | 131 |
| 8 | Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 89-95. | 0.9 | 129 |
| 9 | Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately to Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620. | 5.6 | 126 |
| 10 | X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300. | 5.6 | 114 |
| 11 | Primary Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 189-220. | 3.3 | 88 |
| 12 | Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. <i>Cell</i> , 2020, 180, 878-894.e19. | 28.9 | 82 |
| 13 | The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596. | 2.9 | 74 |
| 14 | Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016, 168, 25-29. | 3.2 | 68 |
| 15 | Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Use. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 99-111. | 3.4 | 63 |
| 16 | Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017, 13, e1006820. | 3.5 | 60 |
| 17 | Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2006, 54, 2434-2440. | 6.7 | 56 |
| 18 | Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359. | 1.9 | 54 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study. <i>Journal of Rheumatology</i> , 2011, 38, 2215-2217. | 2.0 | 47 |
| 20 | Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. <i>Arthritis and Rheumatism</i> , 2012, 64, 1316-1322. | 6.7 | 45 |
| 21 | Sleep disordered breathing in patients with primary Sjögren's syndrome: A group controlled study. <i>Sleep Medicine</i> , 2012, 13, 1066-1070. | 1.6 | 42 |
| 22 | Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2003, 30, 2406-12. | 2.0 | 42 |
| 23 | Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. <i>European Journal of Immunology</i> , 1997, 27, 178-182. | 2.9 | 37 |
| 24 | Neutralization of Muscarinic Receptor Autoantibodies by Intravenous Immunoglobulin in Sjögren Syndrome. <i>Human Immunology</i> , 2005, 66, 411-416. | 2.4 | 36 |
| 25 | Mild autonomic dysfunction in primary Sjögren's syndrome: a controlled study. <i>Arthritis Research and Therapy</i> , 2008, 10, R31. | 3.5 | 36 |
| 26 | Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 2187-2192. | 5.6 | 35 |
| 27 | Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. <i>Arthritis Research and Therapy</i> , 2012, 14, R28. | 3.5 | 34 |
| 28 | Low Copy Number of the Fcγ3 Receptor 3B Gene <i>FCGR3B</i> Is a Risk Factor for Primary Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2012, 39, 2142-2147. | 2.0 | 33 |
| 29 | Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. <i>Arthritis Care and Research</i> , 2016, 68, 1616-1623. | 3.4 | 31 |
| 30 | Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Journal of Rheumatology</i> , 2018, 45, 405-410. | 2.0 | 31 |
| 31 | Upper Airway Surface Tension but not Upper Airway Collapsibility is Elevated in Primary Sjögren's Syndrome. <i>Sleep</i> , 2008, 31, 367-374. | 1.1 | 27 |
| 32 | Nonprecipitating Anti-La(SS-B) Autoantibodies in Primary Sjögren's Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1996, 79, 314-318. | 2.0 | 26 |
| 33 | Activation of the Alternative NF-κB Pathway Improves Disease Symptoms in a Model of Sjogren's Syndrome. <i>PLoS ONE</i> , 2011, 6, e28727. | 2.5 | 26 |
| 34 | Rapid and sensitive detection of anti-ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. <i>Pathology</i> , 1996, 28, 54-57. | 0.6 | 25 |
| 35 | Risk of cancer in patients with biopsy-proven giant cell arteritis. <i>Rheumatology</i> , 2010, 49, 756-759. | 1.9 | 23 |
| 36 | Tertiary lymphoid organs in recalcitrant chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1371-1373.e6. | 2.9 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | How Does Autoimmunity to La and Ro Initiate and Spread?. <i>Autoimmunity</i> , 1994, 18, 87-92. | 2.6 | 18 |
| 38 | Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2013, 15, R71. | 3.5 | 17 |
| 39 | Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255. | 1.9 | 12 |
| 40 | Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174. | 0.8 | 12 |
| 41 | <i>PTPN22</i> R620W minor allele is a genetic risk factor for giant cell arteritis. <i>RMD Open</i> , 2016, 2, e000246. | 3.8 | 9 |
| 42 | <i>47XXY</i> and <i>47XXX</i> in Scleroderma and Myositis. <i>ACR Open Rheumatology</i> , 2022, 4, 528-533. | 2.1 | 8 |
| 43 | Susceptibility for Lupus Nephritis by Low Copy Number of the <i>FCGR3B</i> Gene Is Linked to Increased Levels of Pathogenic Autoantibodies. <i>Autoimmune Diseases</i> , 2013, 2013, 1-6. | 0.6 | 6 |
| 44 | Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542. | 1.8 | 6 |
| 45 | Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren's syndrome. <i>Joint Bone Spine</i> , 2019, 86, 393-395. | 1.6 | 4 |
| 46 | When B cells break bad: development of pathogenic B cells in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 271-282. | 0.8 | 4 |
| 47 | Increased Serum IgG4 Associates with Asthma and Tissue Eosinophilia in Chronic Rhinosinusitis Patients. <i>Pathogens</i> , 2020, 9, 828. | 2.8 | 2 |
| 48 | Primary Sjögren's syndrome in South Australia. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 57-63. | 0.8 | 2 |
| 49 | Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94. | 0.8 | 2 |
| 50 | Humoral immunity to Ro52 is not associated with the Ro52 9571 C/T polymorphism in Australian patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2003, 48, 3293-3294. | 6.7 | 1 |
| 51 | No Association between <i>FCÎR3B</i> Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis. <i>Arthritis</i> , 2013, 2013, 1-4. | 2.0 | 1 |
| 52 | Serum soluble Fas and Fas ligand (FasL) in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 254-256. | 0.8 | 1 |
| 53 | Response to: The interaction of Sjogren's syndrome, gastroesophageal reflux and sleep by Tufik et al.. <i>Sleep Medicine</i> , 2013, 14, 222-223. | 1.6 | 0 |
| 54 | Muscarinic receptor autoantibodies in Sjögren's syndrome. , 2004, , 233-239. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Sjögren's Syndrome in Australia: Clinical Practice and Research. , 2011, , 423-424. | | 0 |
| 56 | Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174. | 0.8 | 0 |